Safety, feasibility, and effectiveness of virtual pulmonary rehabilitation in the real world.
Aged
Aged, 80 and over
Chronic Disease
Exercise Tolerance
Feasibility Studies
Female
Humans
Lung
/ physiopathology
Lung Diseases
/ diagnosis
Male
Middle Aged
Patient Care Team
Program Evaluation
Quality of Life
Recovery of Function
Remote Consultation
Telerehabilitation
Time Factors
Treatment Outcome
Walk Test
prudent healthcare
pulmonary rehabilitation
telemedicine
video-linking
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
2
5
2019
pubmed:
2
5
2019
medline:
20
12
2019
Statut:
epublish
Résumé
To assess the feasibility, safety, and effectiveness of a VIrtual PulmonAry Rehabilitation (VIPAR) program in a real-world setting. Twenty-one patients with stable chronic lung disease at a spoke site received (VIPAR) through live video conferencing with a hub where 24 patients were receiving 14 sessions of standard, outpatient, multi-disciplinary pulmonary rehabilitation (PR) in a hospital. We studied three such consecutive PR programs with 6-10 patients at each site. The hub had a senior physiotherapist, occupational therapist, exercise assistant, and guest lecturer, and the spoke usually had only an exercise instructor and nurse present. Uptake, adverse events (AEs), and early clinical changes were compared within and between groups. Travel distances were estimated using zip codes. Mean attendance was 11.0 sessions in the hub and 10.5 sessions in the spoke ( Video-conferencing, which links a local site to a standard PR program is feasible, safe, and demonstrates at least equivalent short-term clinical gains. Throughput can be increased, with less staffing ratios and significantly less traveling.
Identifiants
pubmed: 31040656
doi: 10.2147/COPD.S193827
pii: copd-14-775
pmc: PMC6459142
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775-780Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Lancet Respir Med. 2014 Mar;2(3):195-203
pubmed: 24621681
Eur Respir J. 2005 Oct;26(4):630-6
pubmed: 16204593
Chest. 2007 May;131(5 Suppl):4S-42S
pubmed: 17494825
Respir Med. 2008 Jun;102(6):819-24
pubmed: 18337077
Lancet. 2000 Jan 29;355(9201):362-8
pubmed: 10665556
PLoS One. 2015 Feb 25;10(2):e0118681
pubmed: 25714962
Eur Respir J. 2006 Apr;27(4):788-94
pubmed: 16481381
Int J Chron Obstruct Pulmon Dis. 2018 Aug 17;13:2473-2482
pubmed: 30154650
Thorax. 2010 May;65(5):423-8
pubmed: 20435864
Ann Intern Med. 2008 Dec 16;149(12):869-78
pubmed: 19075206
Respirology. 2006 Jan;11(1):98-104
pubmed: 16423209
Eur Respir J. 2016 May;47(5):1336-41
pubmed: 27132269
Perspect Psychol Sci. 2015 Mar;10(2):227-37
pubmed: 25910392
Thorax. 2008 Sep;63(9):775-7
pubmed: 18390634
BMJ Open. 2017 Jul 17;7(7):e014580
pubmed: 28716786
Can Respir J. 2011 Jul-Aug;18(4):216-20
pubmed: 22059179
Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793
pubmed: 25705944
Respir Med. 2009 Oct;103(10):1564-71
pubmed: 19481919
Thorax. 2017 Jan;72(1):57-65
pubmed: 27672116
Thorax. 2001 Oct;56(10):779-84
pubmed: 11562517
J Telemed Telecare. 2017 Aug;23(7):639-649
pubmed: 27450573
Respiration. 2012;83(6):499-506
pubmed: 21846962
Int J Chron Obstruct Pulmon Dis. 2014;9:27-39
pubmed: 24368884
Thorax. 2013 Sep;68 Suppl 2:ii1-30
pubmed: 23880483